Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

TLK-286.

Claire F Verschraegen1, Harriet O Smith, Fa Chyi Lee

  • 1University of New Mexico, Cancer Research and Treatment Center, 900 Camino de Salud NE, Albuquerque 87131, USA. cverschraegen@salud.unm.edu

Idrugs : the Investigational Drugs Journal
|August 31, 2004
PubMed
Summary
This summary is machine-generated.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Health Equity for Oncology Patients in Rural America: Insurmountable Challenges or Opportunity to Make a Real Difference.

JCO oncology practice·2026
Same author

CRE26-065: Second-Line Treatments for Patients With Cemiplimab-Refractory Cutaneous Squamous Cell Carcinomas: A Brief Report.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

CRE26-065: Second-Line Treatments for Patients With Cemiplimab-Refractory Cutaneous Squamous Cell Carcinomas: A Brief Report.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Second-line treatments for patients with programmed cell death protein 1-refractory cutaneous squamous cell carcinomas: a brief report.

The oncologist·2026
Same author

Chemoprophylactic effect of PD-1/PD-L1 inhibitor treatment on non-melanoma skin cancer development.

Journal of the American Academy of Dermatology·2025
Same author

Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint Inhibitors.

Cancer investigation·2025
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Telik Inc is developing TLK-286, a novel modified glutathione analog prodrug. This innovative compound shows potential for the treatment of various cancers.

Area of Science:

  • Oncology
  • Medicinal Chemistry

Background:

  • Glutathione is a crucial endogenous antioxidant and detoxifying agent.
  • Cancer cells often exhibit altered glutathione metabolism.
  • Prodrug strategies can enhance drug delivery and efficacy.

Purpose of the Study:

  • To introduce TLK-286, a modified glutathione analog prodrug.
  • To evaluate the potential of TLK-286 in cancer treatment.

Main Methods:

  • Development of a novel prodrug, TLK-286.
  • Preclinical evaluation of TLK-286's anti-cancer properties (details not provided in abstract).

Main Results:

  • TLK-286 is a modified glutathione analog prodrug.
  • The compound is under development for cancer therapy.

Conclusions:

  • TLK-286 represents a potential new therapeutic agent for cancer.
  • Further research and clinical trials are warranted to establish its efficacy and safety.